Dr. Dietrich Stephan is a geneticist, entrepreneur, and CEO of NeuBase Therapeutics. Neubase is biotech startup focused on developing precision genetic medicines.
Dietrich previously founded or co-founded 14 biotechnology companies, was the chair of the Human Genetics department at the University of Pittsburgh, and was the CEO of LifeX Labs, a biotechnology incubator.
Neubase, his latest company, is developing technology spun out of Carnegie Mellon University that aims to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules.
In April 2021 Neubase went public, trading under the ticker symbol NBSE, and has raised over $100 million in less than three years.
In this conversation, Dietrich and Aaron discuss why Neubase went public earlier than most biotech startups, the vicious diseases they are fighting against, and the impact of the Human Genome Project on society.
Dietrich Stephan’s Challenge;
If you liked this interview, check out episode XX with Craig Markovitz where we discuss business building, university technology transfer, and life after a successful startup.
Text Me What You Think of This Episode 412-278-7680
Underwritten by Piper Creative
Piper Creative makes creating podcasts, vlogs, and videos easy.
We work with Fortune 500s, medium-sized companies, and entrepreneurs.
Follow Piper as we grow